Examination of HER3 targeting in cancer using monoclonal antibodies - Wikidata - wikimedia - TriplyDB

Examination of HER3 targeting in cancer using monoclonal antibodies

Examination of HER3 targeting in cancer using monoclonal antibodies

http://www.wikidata.org/entity/Q35031462

about

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.Oligoclonal antibodies to target the ErbB family.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.HER3 over-expression and overall survival in gastrointestinal cancers Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.HER3 as a Therapeutic Target in Cancer.Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.HER3 expression is correlated to distally located and low-grade colon cancer.ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.[The HER3/ERBB3 receptor: the dark side of the ERBB planet].Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling

P2860

Q33691823-3F1856EC-EE71-43F9-9595-5F94478CB862 Q33772914-86228CB2-B60A-45C3-8F51-86828AA41A9D Q34506951-16922585-9E28-44C5-A464-8E6B54BCD90E Q35780145-B32DD695-B002-4633-B5A2-71CF1F741007 Q36021891-CB0735A8-06EE-4745-9495-87F5F0DB9441 Q36356248-A81F76F8-090A-4132-B846-8F429FA57920 Q36387554-52DB6E3F-EB72-46E1-B1A2-62F93FAABF4B Q36619051-B22B6C6D-D364-4DFC-A15F-7E70FC0F4056 Q36797398-052F1F12-CBB3-4ACE-ADEB-804ADF13302F Q37689036-EB9E99BC-E9D3-4330-8DFB-63897B8A7548 Q38623361-3C9CCDFB-5F30-4080-8ABB-336F94EB72FF Q38725101-DD964A35-1948-4927-A38C-BA0B654CEDE2 Q38868047-9964EA59-AC9D-4CD5-BD0D-FF598F7F24E5 Q40918277-7AE33618-2B14-4730-A3F2-75D3CEAACE1A Q41135979-BB2D886B-4C4F-4A5A-8D2B-9FEE75EC596A Q41667670-307FB60F-6949-4CBB-A7BB-2FB5EFB7F92F Q54266767-35D90806-124D-4E63-AC4D-4AF3B7852F07 Q58572182-B98134EA-BA0F-4F52-AF7E-2D3B5129EA7F

P2860

Examination of HER3 targeting in cancer using monoclonal antibodies

http://www.wikidata.org/entity/Q35031462

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Examination of HER3 targeting in cancer using monoclonal antibodies

@ast

Examination of HER3 targeting in cancer using monoclonal antibodies

@en

type

label

Examination of HER3 targeting in cancer using monoclonal antibodies

@ast

Examination of HER3 targeting in cancer using monoclonal antibodies

@en

prefLabel

Examination of HER3 targeting in cancer using monoclonal antibodies

@ast

Examination of HER3 targeting in cancer using monoclonal antibodies

@en

P1433

Q35031462-5D0C1272-D9FC-4657-85C4-ED2AAAA03D50

P1476

Q35031462-5C8A599E-D2F6-4D2D-915C-1B818F08F235

P2093

Q35031462-16AC16A6-5D80-4B9A-A667-A75D40E7E111

Q35031462-3A0E204A-A8E2-46BC-A0BB-7CE77EAB882D

Q35031462-5479600F-C8D9-4391-9C2C-1C527A195A35

Q35031462-5888F2EB-88E4-4621-82AF-F0D410D0D40E

Q35031462-5BEDD4BF-0CDF-439B-9947-13B1DBCA8B94

Q35031462-646ACEA9-3E73-4386-A5BF-78D1029CDDC1

Q35031462-6DD934FE-88BB-4B90-ABCD-68A2DD25E3AB

Q35031462-88AF0FD9-C069-48B6-89B6-E1E7548CB250

Q35031462-B06C6821-29F9-4333-9A0F-B2E117C4692B

Q35031462-CF687D52-1C5B-4A24-8F83-720BDAEAA426

P2860

Q35031462-018124AE-3BFE-41B2-AE7B-50CDE22A2DC5

Q35031462-02F0204D-66AB-4463-BA62-CD2EEC8E8A17

Q35031462-036C06DC-C4F6-4F71-8511-15BB4D8E212A

Q35031462-0B6792EE-2E95-4782-8A26-DAAB441A7AB0

Q35031462-0CC25D54-E311-4BE8-B858-576FCC1EB31B

Q35031462-0E5A5AD4-AC2E-484C-B9A2-60E17DDA582D

Q35031462-1B56E79E-A667-465B-88AA-DCFF520C0C74

Q35031462-1C0CA4F3-B738-4767-9791-AFEC88D9EDAE

Q35031462-1E14A6C5-C8A3-45C8-A791-EF9700BA458B

Q35031462-2C0A78EE-5704-47EE-9017-DA4DB5D316A2

P304

Q35031462-9029D574-BFA3-4995-858C-DBC6E61B8D0B

P31

Q35031462-3600F646-3331-40B5-844F-60D23B8D4D2E

P356

Q35031462-DF7D3BC8-F319-486D-9175-3467C935119F

P407

Q35031462-1BB31827-6D11-45E6-8098-3944BE3F169D

P433

Q35031462-6569FDB9-BB8E-439C-B91B-1CEBEBBF482C

P478

Q35031462-A97B2BF5-4EEA-4935-89D9-DC3D5AB941A3

P50

Q35031462-6B2E4F1E-D034-4A37-81F5-D4ED2D8B74B1

Q35031462-C2943671-326A-48B8-8426-7FF16A56DC16

P577

Q35031462-8936BB76-86FE-4D21-9806-6C5FA6423659

P5875

Q35031462-BF2C766E-F978-417F-82B7-4ED7C6FB6B80

P698

Q35031462-D9444579-8B75-44A8-BDF7-0FC19AEB6479

P932

Q35031462-E5B31927-6BDC-42B3-9787-D3746403A803

P356

PNAS.1423645112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Examination of HER3 targeting in cancer using monoclonal antibodies

@en

P2093

Ali Abdul-Hai

http://www.w3.org/2001/XMLSchema#string

André Pèlegrin

http://www.w3.org/2001/XMLSchema#string

Christel Larbouret

http://www.w3.org/2001/XMLSchema#string

Lucile Mounier

http://www.w3.org/2001/XMLSchema#string

Maicol Mancini

http://www.w3.org/2001/XMLSchema#string

Manjusha Ghosh

http://www.w3.org/2001/XMLSchema#string

Michael Sela

http://www.w3.org/2001/XMLSchema#string

Moshit Lindzen

http://www.w3.org/2001/XMLSchema#string

Myriam Chentouf

http://www.w3.org/2001/XMLSchema#string

Nadège Gaborit

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic ERBB3 mutations in human cancers

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

Untangling the ErbB signalling network

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor rec

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

Grb2 regulates internalization of EGF receptors through clathrin-coated pits.

P304

839-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1423645112

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Chardès

P577

2015-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273167935

http://www.w3.org/2001/XMLSchema#string

P698

25564668

http://www.w3.org/2001/XMLSchema#string

P932

4311849

http://www.w3.org/2001/XMLSchema#string